ReviewAtherosclerosis2023
Clinical applications of polygenic risk score for coronary artery disease through the life course.
Review in Atherosclerosis, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Baseline Computed Tomography Coronary Angiography and Polygenic Risk Profiles in Adults With Type 2 Diabetes: A Cross-Sectional Analysis From the VOLTAIRE Study.Diabetes, obesity & metabolism · 2026Trial
- Evaluating the impact of communicating high polygenic risk for coronary artery disease on the health behaviour of young overweight adults: a pragmatic randomised controlled trial.Scientific reports · 2026Trial
- Pervasive interactions between exposures and polygenic risk can inform more effective clinical and behavioral interventions.Nature genetics · 2026Article
- Article
- An integrated germline and somatic genomic model for coronary artery disease.Nature communications · 2026Article
- Economic modeling of polygenic risk prediction of coronary artery disease in childhood.NPJ cardiovascular health · 2026Article
- Unraveling the genetic blueprint of coronary artery disease: The role of polygenic risk scores in risk prediction.American heart journal plus : cardiology research and practice · 2026Article
- Genomic Perspective on Heterogeneity of Organs and Body Aging.Aging cell · 2026Review
- A comprehensive review of ischemic heart disease: pathophysiology, current treatments, natural products-based therapies, and nanotherapeutics.Frontiers in pharmacology · 2026Review
- Polygenic risk scores in healthcare contexts: what's the scope? An interview study of European healthcare providers and researchers' perspectives on ethical challenges.Human genetics · 2025Article
- Genomic and Precision Medicine Approaches in Atherosclerotic Cardiovascular Disease: From Risk Prediction to Therapy-A Review.Biomedicines · 2025Review
- Appraisal of multiple polygenic risk scores to estimate the risk of myocardial infarction and coronary artery lesions.Communications medicine · 2025Article
- Precision Medicine in Cardiovascular Disease Prevention: Clinical Validation of Multi-Ancestry Polygenic Risk Scores in a U.S. Cohort.Nutrients · 2025Article
- Breaking binary in cardiovascular disease risk prediction.NPJ cardiovascular health · 2025Review
- Genomic Drivers of Coronary Artery Disease and Risk of Future Outcomes After Coronary Angiography.JAMA network open · 2025Article
- Blood Lipid Polygenic Risk Score Development and Application for Atherosclerosis Ultrasound Parameters.Biomedicines · 2024Article
- Polygenic Risk Is Associated With Long-Term Coronary Plaque Progression and High-Risk Plaque.JACC. Cardiovascular imaging · 2024Article
- Dual exposure-by-polygenic score interactions highlight disparities across social groups in the proportion needed to benefit.medRxiv : the preprint server for health sciences · 2024Article
- Assessment Timings of Polygenic Risk Score for Atherosclerotic Cardiovascular Disease.Journal of atherosclerosis and thrombosis · 2024Article
- Risk of adverse cardiovascular events based on common genetic variants in 8-year follow-up of the LIPIDOGEN2015 population using the polygenic risk score (PRS): study design and methodology.Archives of medical science : AMS · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Coronary artery disease (CAD) remains a leading cause of morbidity and mortality worldwide, highlighting the limitations of current primary and secondary prevention frameworks. In this review, we detail how the polygenic risk score for CAD can improve our current preventive and treatment frameworks across three clinical applications that span the life course: (i) identification and treatment of people at increased risk early in the life course prior to the onset of clinical risk factors, (ii) improving the precision around risk estimation in middle age, and (ii) guiding treatment decisions and enabling more efficient clinical trials even after the onset of CAD. We end by summarizing the efforts needed as we head towards more widespread use of polygenic risk score for CAD in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.